DocSym
β
Searchsearch
Search
(E21.1) Secondary hyperparathyroidism, not elsewhere classified
More details coming soon
601 184 in individuals diagnosis secondary hyperparathyroidism, not elsewhere classified confirmed
6 728 deaths with diagnosis secondary hyperparathyroidism, not elsewhere classified
1% mortality rate associated with the disease secondary hyperparathyroidism, not elsewhere classified
Diagnosis secondary hyperparathyroidism, not elsewhere classified is diagnosed Women are 52.72% more likely than Men
142 132
Men receive the diagnosis secondary hyperparathyroidism, not elsewhere classified
1 512 (1.1 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
459 052
Women receive the diagnosis secondary hyperparathyroidism, not elsewhere classified
5 216 (1.1 %)Died from this diagnosis.
Risk Group for the Disease secondary hyperparathyroidism, not elsewhere classified - Men aged 65-69 and Women aged 60-64
In Men diagnosis is most often set at age 0-94
Less common in men the disease occurs at Age 95+Less common in women the disease occurs at Age 5-9
In Women diagnosis is most often set at age 0-5, 10-95+
Disease Features secondary hyperparathyroidism, not elsewhere classified
Absence or low individual and public risk
Secondary hyperparathyroidism, not elsewhere classified - what does this mean
Secondary hyperparathyroidism, not elsewhere classified, occurs when excessive secretion of parathyroid hormone leads to an increase in the serum calcium level, resulting in a decrease in serum phosphate levels. this can be caused by a variety of conditions, including renal failure, vitamin d deficiency, or certain medications.
What happens during the disease - secondary hyperparathyroidism, not elsewhere classified
Secondary hyperparathyroidism is caused by an underlying condition that leads to a decrease in the production of active vitamin d in the body. this decrease in active vitamin d causes a decrease in calcium absorption from the gut, leading to hypocalcaemia. the body responds to this hypocalcaemia by releasing parathyroid hormone, which in turn causes an increase in the activity of the parathyroid glands. this increase in activity leads to hyperparathyroidism, resulting in increased calcium levels and decreased phosphorus levels.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Medical history and physical examination
- Blood tests to measure calcium, phosphate, parathyroid hormone levels, and alkaline phosphatase
- X-ray imaging of the bones and parathyroid glands
- Ultrasound imaging of the parathyroid glands
- Sestamibi scan of the parathyroid glands
- CT scan of the neck
- MRI of the neck
- Urine tests to measure calcium and phosphate levels
Treatment and Medical Assistance
Main Goal of Treatment: To reduce the symptoms of Secondary Hyperparathyroidism, not elsewhere classified.
- Prescribe medications to reduce calcium levels in the blood
- Monitor calcium and phosphorus levels in the blood
- Prescribe medications to reduce parathyroid hormone levels in the blood
- Prescribe medications to reduce the production of parathyroid hormone
- Prescribe vitamin D supplements
- Prescribe calcium supplements
- Provide dietary guidance to reduce calcium intake
- Provide dietary guidance to increase phosphorus intake
- Provide lifestyle guidance to reduce stress
- Refer patient to endocrinologist for further evaluation and treatment
10 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Secondary hyperparathyroidism, not elsewhere classified - Prevention
Secondary hyperparathyroidism, not elsewhere classified, can be prevented by maintaining adequate levels of calcium and vitamin d in the diet, avoiding prolonged periods of low calcium intake, and avoiding certain medications that can interfere with calcium absorption.